The general pattern of biodistribution, tumor uptake, tumor-to-blood ratio, and hepatic uptake of [89Zr]Zr-DFO-seribantumab appear to be comparable to other reported HER3-targeting 89Zr-labeled antibodies [17,35,36]. The gene discussed is ERBB3; the disease is neoplasm.